Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Gut

• Publication date

  1993-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gut.34.5.676PMID 8504970PMCID PMC1374188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis

  2005cited by this paper
• The rectal mucosa-associated microflora in patients with ulcerative colitis.

  1992cited by this paper
• The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology.

  1991cited by this paper
• Is anterior resection without a defunctioning colostomy safe

  1991cited by this paper
• Safety and pharmacokinetics: colloidal bismuth subcitrate.

  1991cited by this paper
• The mode of action of colloidal bismuth subcitrate.

  1991cited by this paper
• Tripotassium dicitrato bismuthate enemas in the treatment of ulcerative proctitis

  1990cited by this paper
• Rectal bismuth subsalicylate as therapy for ulcerative colitis

  1990cited by this paper
• Bismuth therapy in gastrointestinal diseases.

  1990cited by this paper
• Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.

  1990cited by this paper
• Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate.

  1990cited by this paper
• The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate

  1989cited by this paper
• Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate

  1989cited by this paper
• Safety and efficacy of acetarsol suppositories in unresponsive proctitis

  1989cited by this paper
• Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea.

  1988cited by this paper
• 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

  1987cited by this paper
• Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis

  1982cited by this paper
• Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

  1981cited by this paper
• Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.

  1976cited by this paper
• Determination of bismuth in blood and urine.

  1976cited by this paper
• Experimental and Clinical Studies on Rifampicin in Treatment of Leprosy

  1970cited by this paper
• COMPARISON OF ACETARSOL AND PREDNISOLONE-21-PHOSPHATE SUPPOSITORIES IN THE TREATMENT OF IDIOPATHIC PROCTITIS.

  1965cited by this paper
• Variation Between Observers in Describing Mucosal Appearances in Proctocolitis*

  1964cited by this paper
• [Use of bismuth in gastroenterology].

  1962cited by this paper
• Noradrenaline in Acute Peripheral Circulatory Failure

  1956cited by this paper
• Biopsy Studies in Ulcerative Colitis

  1956cited by this paper
• FINAL REPORT ON A THERAPEUTIC TRIAL

  1955cited by this paper
• Saint and Pioneer

  1950cited by this paper
• Aplastic Anaemia with Recovery

  1938cited by this paper
• MATERIAL FEVER IN ST. LUCIA, W.I

  1902cited by this paper

• Use of Bismuth in Irritable Bowel Syndrome

  2021cites this paper
• Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

  2019cites this paper
• Bismuth(III) interactions with Desulfovibrio desulfuricans: inhibition of cell energetics and nanocrystal formation of Bi2S3 and Bi0

  2019cites this paper
• Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

  2019cites this paper
• Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

  2019cites this paper
• Drug Therapy for Gastrointestinal and Liver Diseases

  2019influential citation
• Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease

  2018cites this paper
• Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.

  2017cites this paper
• Novel Nonbiologic Therapies for Ulcerative Colitis

  2014cites this paper
• Oral bismuth for chronic intractable diarrheal conditions?

  2013cites this paper
• High mucosal healing rates in 5‐ASA‐treated ulcerative colitis patients: Results of a meta‐analysis of clinical trials

  2012cites this paper
• Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis

  2012cites this paper
• Validity of activity indices in ulcerative colitis— comparison of clinical indices and endoscopic indices—

  2011cites this paper
• Topical agents for idiopathic distal colitis and proctitis

  2011cites this paper
• Is 5-ASA still the treatment of choice for ulcerative colitis?

  2011cites this paper
• Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

  2010cites this paper
• VALIDITY OF ACTIVITY INDICES IN ULCERATIVE COLITIS: COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES

  2010cites this paper
• Pouchitis After Restorative Proctocolectomy

  2010cites this paper
• Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.

  2010cites this paper
• A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index

  2008cites this paper
• European evidence-based Consensus on the management of ulcerative colitis: Current management.

  2008cites this paper
• European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

  2008cites this paper
• Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis

  2008cites this paper
• Meta-Analysis of the Placebo Response in Ulcerative Colitis

  2008cites this paper
• Pharmacotherapy for Microscopic Colitis

  2007cites this paper
• Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report

  2005cites this paper
• Efficacy of Rebamipide Enemas in Active Distal Ulcerative Colitis and Proctitis: A Prospective Study Report

  2005cites this paper
• Medical management of ulcerative colitis

  2003cites this paper
• 30 Medical management of ulcerative colitis

  2003cites this paper
• Epidermal growth factor for ulcerative colitis.

  2003cites this paper
• A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis

  2002cites this paper
• Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

  2002cites this paper
• REVIEW: Role of 5-Aminosalicylic Acid (5-ASA) in Treatment of Inflammatory Bowel Disease: A Systemic Review

  2002cites this paper
• Hydrogen Sulfide and Colonic Epithelial Metabolism

  2001cites this paper
• Hydrogen sulfide and colonic epithelial metabolism: implications for ulcerative colitis.

  2001cites this paper
• Oral versus combination mesalazine therapy in active ulcerative colitis: a double‐blind, double‐dummy, randomized multicentre study

  2001cites this paper
• THE MANAGEMENT OF REFRACTORY DISTAL COLITIS

  2001cites this paper
• Inhibition of inducible nitric oxide synthase in the human intestinal epithelial cell line, DLD-1, by the inducers of heme oxygenase 1, bismuth salts, heme, and nitric oxide donors

  2000cites this paper
• A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis

  2000cites this paper
• Collagenous colitis treated successfully with bismuth subsalicylate.

  2000cites this paper
• Therapeutic Role for Bismuth Compounds in TNBS-Induced Colitis in the Rat

  2000cites this paper
• Site of Bismuth Absorption from Bismuth Subsalicylate

  2000cites this paper
• Case Report: Collagenous Colitis Treated Successfully with Bismuth Subsalicylate

  2000cites this paper
• Site of bismuth absorption from bismuth subsalicylate: implications for treatment of colonic conditions.

  2000cites this paper
• Medical therapy for induction and maintenance of remission in pouchitis: a systematic review.

  1999cites this paper
• Medical therapy of inflammatory bowel disease.

  1999cites this paper
• Medical Therapy for Induction and Maintenance of Remission in Pouchitis: A Systematic Review

  1999cites this paper
• Novel therapies for inflammatory bowel disease.

  1999cites this paper
• Pharmacotherapy for inducing and maintaining remission in pouchitis.

  1998cites this paper
• UNCONVENTIONAL TREATMENTS FOR INFLAMMATORY BOWEL DISEASE

  1998cites this paper
• A Meta-Analysis to Assess the Incidence of Adverse Effects Associated with the Transdermal Nicotine Patch

  1998cites this paper
• Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon.

  1998cites this paper
• Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis.

  1998cites this paper
• Ulcerative colitis: an epithelial disease?

  1997cites this paper
• Long‐term efficacy of bismuth carbomer enemas in patients with treatment‐resistant chronic pouchitis

  1997cites this paper
• Innovations in topical therapy.

  1997cites this paper
• 7 Innovations in topical therapy

  1997cites this paper
• A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.

  1997cites this paper
• ENEMALAR VE ENEMA FORMÜLASYONLARINDA YENİ GELİŞMELER ENEMAS AND NEW DEVELOPMENTS IN ENEMA FORMULATIONS : ENEMAS AND NEW DEVELOPMENTS IN ENEMA FORMULATIONS

  1997cites this paper
• 2 Ulcerative colitis: an epithelial disease?

  1997cites this paper
• Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double‐blind, placebo‐controlled trial

  1997cites this paper
• A Comparative Review of Topical Therapies for Inflammatory Bowel Disease

  1996cites this paper
• Colonic mucus, smoking and ulcerative colitis.

  1996cites this paper
• New therapeutic approaches.

  1995cites this paper
• Therapeutic effect of colloid bismuth subcitrate in experimental colitis in the rat.

  1995cites this paper
• Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens.

  1995cites this paper
• Medical therapy of ulcerative proctitis and proctosigmoiditis, including refractory disease.

  1995cites this paper
• Rectal aminosalicylate therapy for distal ulcerative colitis: a meta‐analysis

  1995cites this paper
• Inflammatory Bowel Disease

  1994cites this paper
• Medical therapy for inflammatory bowel disease.

  1994cites this paper
• Gastroenterology--II: Small and large bowel, pancreas and biliary system.

  1994cites this paper
• Ulcerative colitis and xenobiotic metabolism.

  1994cites this paper